BioCentury | Apr 4, 2020
Finance

Steady as venBio goes

A day after Arch and Flagship unveiled dueling billion dollar funds, venBio is staying the course with a more modest $394 million fund. What is new for the nine-year-old firm is a dramatic shift away...
BioCentury | Apr 3, 2020
Deals

Servier adds mAb platform via takeout of former European biotech darling Symphogen

What was once a high-profile European biotech is now going out quietly as Servier is acquiring Danish mAb company Symphogen A/S for an undisclosed sum. The two companies are partnered across three clinical stage immuno-oncology...
BioCentury | Mar 28, 2020
Management Tracks

Bernard joins Qiagen as CEO; plus CytomX, Recursion, 89bio, Heptares, Fusion, Freeline, Cognition, I-Mab, Seres and more

Qiagen N.V. (NYSE:QGEN; Xetra:QIA) said Thierry Bernard will become the permanent CEO after serving on an interim basis since October. Bernard, who joined Qiagen in 2015 as SVP of the molecular diagnostics business area, takes...
BioCentury | Mar 27, 2020
Regulation

CHMP decisions set stage for approval of Novartis’ SMA gene therapy, Celgene’s Zeposia for MS, Sanofi’s comeback cancer drug

EMA’s CHMP backed conditional approval of an MAA for Zolgensma to treat spinal muscular atrophy in its March set of recommendations, which were made via a virtual meeting because of the COVID-19 outbreak. The agency...
BioCentury | Mar 27, 2020
Emerging Company Profile

Redpin debuts chemogenetic platform for neurology, raises $15.5M

Redpin emerged from stealth Wednesday with a $15.5 million series A round and a chemogenetics platform designed to treat neurological disorders by controlling neuron excitability. 4Bio Capital and Arkin Bio Ventures led the tranched round....
BioCentury | Mar 27, 2020
Deals

Takeda pursuing exosome therapies through Evox deal

Takeda is betting on Evox’s exosome drug delivery technology via a partnership to develop five protein replacement and mRNA therapies for rare diseases. Evox Therapeutics Ltd., an Oxford, U.K.-based biotech, is eligible to receive up...
BioCentury | Mar 25, 2020
Product Development

Repurposing candidates for COVID-19 from UCSF, Aldeyra

A UCSF team has keyed in on more than five dozen compounds against nearly as many targets that could be repurposed to target the virus behind COVID-19. Meanwhile, a repurposing screen by Aldeyra could yield...
BioCentury | Mar 20, 2020
Product Development

Mount Sinai develops antibody test for COVID-19

An antibody-based assay from the Icahn School of Medicine at Mount Sinai could help epidemiologists better determine how and where COVID-19 is spreading, and how many people have been infected. It could also find donors...
BioCentury | Mar 4, 2020
Product Development

Biopharma broadens fight vs. COVID-19 as Alnylam, Takeda unveil new programs

The biopharma industry is bringing additional modalities into the fight against COVID-19, with Vir and Alnylam developing an siRNA therapeutic while Takeda adds a plasma-based approach from COVID-19 survivors. Both programs will broaden and potentially...
BioCentury | Mar 3, 2020
Product Development

Following Phase III readout, Karyopharm seeks approval of Xpovio for second-line MM

Karyopharm gained $11.38 (70%) to $27.72 on Monday, adding about $746 million in market value, after announcing that Xpovio selinexor met the primary endpoint of improving PFS in the confirmatory Phase III BOSTON trial to...
Items per page:
1 - 10 of 3706
BioCentury | Apr 4, 2020
Finance

Steady as venBio goes

A day after Arch and Flagship unveiled dueling billion dollar funds, venBio is staying the course with a more modest $394 million fund. What is new for the nine-year-old firm is a dramatic shift away...
BioCentury | Apr 3, 2020
Deals

Servier adds mAb platform via takeout of former European biotech darling Symphogen

What was once a high-profile European biotech is now going out quietly as Servier is acquiring Danish mAb company Symphogen A/S for an undisclosed sum. The two companies are partnered across three clinical stage immuno-oncology...
BioCentury | Mar 28, 2020
Management Tracks

Bernard joins Qiagen as CEO; plus CytomX, Recursion, 89bio, Heptares, Fusion, Freeline, Cognition, I-Mab, Seres and more

Qiagen N.V. (NYSE:QGEN; Xetra:QIA) said Thierry Bernard will become the permanent CEO after serving on an interim basis since October. Bernard, who joined Qiagen in 2015 as SVP of the molecular diagnostics business area, takes...
BioCentury | Mar 27, 2020
Regulation

CHMP decisions set stage for approval of Novartis’ SMA gene therapy, Celgene’s Zeposia for MS, Sanofi’s comeback cancer drug

EMA’s CHMP backed conditional approval of an MAA for Zolgensma to treat spinal muscular atrophy in its March set of recommendations, which were made via a virtual meeting because of the COVID-19 outbreak. The agency...
BioCentury | Mar 27, 2020
Emerging Company Profile

Redpin debuts chemogenetic platform for neurology, raises $15.5M

Redpin emerged from stealth Wednesday with a $15.5 million series A round and a chemogenetics platform designed to treat neurological disorders by controlling neuron excitability. 4Bio Capital and Arkin Bio Ventures led the tranched round....
BioCentury | Mar 27, 2020
Deals

Takeda pursuing exosome therapies through Evox deal

Takeda is betting on Evox’s exosome drug delivery technology via a partnership to develop five protein replacement and mRNA therapies for rare diseases. Evox Therapeutics Ltd., an Oxford, U.K.-based biotech, is eligible to receive up...
BioCentury | Mar 25, 2020
Product Development

Repurposing candidates for COVID-19 from UCSF, Aldeyra

A UCSF team has keyed in on more than five dozen compounds against nearly as many targets that could be repurposed to target the virus behind COVID-19. Meanwhile, a repurposing screen by Aldeyra could yield...
BioCentury | Mar 20, 2020
Product Development

Mount Sinai develops antibody test for COVID-19

An antibody-based assay from the Icahn School of Medicine at Mount Sinai could help epidemiologists better determine how and where COVID-19 is spreading, and how many people have been infected. It could also find donors...
BioCentury | Mar 4, 2020
Product Development

Biopharma broadens fight vs. COVID-19 as Alnylam, Takeda unveil new programs

The biopharma industry is bringing additional modalities into the fight against COVID-19, with Vir and Alnylam developing an siRNA therapeutic while Takeda adds a plasma-based approach from COVID-19 survivors. Both programs will broaden and potentially...
BioCentury | Mar 3, 2020
Product Development

Following Phase III readout, Karyopharm seeks approval of Xpovio for second-line MM

Karyopharm gained $11.38 (70%) to $27.72 on Monday, adding about $746 million in market value, after announcing that Xpovio selinexor met the primary endpoint of improving PFS in the confirmatory Phase III BOSTON trial to...
Items per page:
1 - 10 of 3706